Ziyu Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ziyu Guo has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jingang Zheng
China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication - Qinfeng Xu
Shandong Provincial Engineering Laboratory of Urologic Tissue Reconstruction, Jinan, China
1 shared publication - Yike Li
Department of Cardiology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
1 shared publication - Zixiang Ye
Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No 167 North Lishi Road, Xicheng District, Beijing, 100037, China, 86 88398866
1 shared publication
Latest Publications
- Open Access
- 16 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (12) , e70104
Association of liver fibrosis scores with all‐cause and cardiovascular mortality in patients with heart failure
The aim of this study was to examine the relationship of liver fibrosis (determined via fibrosis scores) with all‐cause mortality and cardiovascular mortality in HF patients. The study examined demographic and clinical data were collected from NHANES database (1999 to 2018). A total of 1356 HF patients were enrolled in our analysis. During a median follow‐up time of 70 months, 455 patients died. Compared to the survivors, the death group showed significantly elevated LFSs levels. RCS analysis revealed a linear relationship between various LFSs and all‐cause and cardiovascular mortality. KM curves and Cox regression models indicated that higher FIB‐4 (≥ 1.637), NFS (≥ −0.064), and AST/ALT ratio (≥ 1.172) were linked to higher risk of all‐cause mortality [Cox model 2: FIB‐4 adjusted hazard ratio (aHR), 1.24; 95% CI, 1.04–1.48; NFS aHR, 1.19; 95% CI, 1.01–1.38; AST/ALT ratio aHR, 1.25; 95% CI, 1.07–1.47] and cardiovascular mortality in heart failure patients (FIB‐4 aHR, 1.28; 95% CI, 1.07–1.67; AST/ALT ratio aHR, 1.39; 95% CI, 1.08–1.79). ROC curves indicated that FIB‐4, NFS, and the AST/ALT ratio were important predicators of all‐cause mortality (AUC: 0.715, 0.707, and 0.715, respectively) and cardiovascular mortality (AUC: 0.658, 0.657, and 0.659, respectively) in heart failure patients. Random survival forests showed that FIB‐4, AST/ALT ratio, and NFS emerged as important factors potentially influencing mortality of HF. Consistent associations were observed in subgroup analysis. Liver fibrosis scores (FIB‐4, NFS, and AST/ALT ratio) were strongly linked to all‐cause and cardiovascular mortality in heart failure patients.
- 16 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (12) , e70104
Open AccessAssociation of liver fibrosis scores with all‐cause and cardiovascular mortality in patients with heart failure
The aim of this study was to examine the relationship of liver fibrosis (determined via fibrosis scores) with all‐cause mortality and cardiovascular mortality in HF patients. The study examined demographic and clinical data were collected from NHANES database (1999 to 2018). A total of 1356 HF patients were enrolled in our analysis. During a median follow‐up time of 70 months, 455 patients died. Compared to the survivors, the death group showed significantly elevated LFSs levels. RCS analysis revealed a linear relationship between various LFSs and all‐cause and cardiovascular mortality. KM curves and Cox regression models indicated that higher FIB‐4 (≥ 1.637), NFS (≥ −0.064), and AST/ALT ratio (≥ 1.172) were linked to higher risk of all‐cause mortality [Cox model 2: FIB‐4 adjusted hazard ratio (aHR), 1.24; 95% CI, 1.04–1.48; NFS aHR, 1.19; 95% CI, 1.01–1.38; AST/ALT ratio aHR, 1.25; 95% CI, 1.07–1.47] and cardiovascular mortality in heart failure patients (FIB‐4 aHR, 1.28; 95% CI, 1.07–1.67; AST/ALT ratio aHR, 1.39; 95% CI, 1.08–1.79). ROC curves indicated that FIB‐4, NFS, and the AST/ALT ratio were important predicators of all‐cause mortality (AUC: 0.715, 0.707, and 0.715, respectively) and cardiovascular mortality (AUC: 0.658, 0.657, and 0.659, respectively) in heart failure patients. Random survival forests showed that FIB‐4, AST/ALT ratio, and NFS emerged as important factors potentially influencing mortality of HF. Consistent associations were observed in subgroup analysis. Liver fibrosis scores (FIB‐4, NFS, and AST/ALT ratio) were strongly linked to all‐cause and cardiovascular mortality in heart failure patients.